NNMX Stock - Nanomix Corporation
Unlock GoAI Insights for NNMX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $15,450 | $141,778 | $60,375 | $16,329 | $31,723 |
| Gross Profit | $-69,458 | $77,181 | $32,044 | $-158,710 | $-193,606 |
| Gross Margin | -449.6% | 54.4% | 53.1% | -972.0% | -610.3% |
| Operating Income | $-8,437,168 | $-5,725,151 | $-4,906,360 | $-3,493,240 | $-2,033,410 |
| Net Income | $-12,332,976 | $-11,682,209 | $-7,478,386 | $-3,694,079 | $-3,601,217 |
| Net Margin | -79825.1% | -8239.8% | -12386.6% | -22622.8% | -11352.1% |
| EPS | $-0.00 | $-2.20 | $-1739.86 | $-5.75 | $-6.08 |
Boston Therapeutics, Inc. develops, manufactures, and commercializes therapeutic drugs to address unmet medical needs in diabetes and inflammatory diseases. The company develops BTI-320, a non-systemic carbohydrate-based compound tablet that is in Phase II clinical trial for reduction of post-meal blood glucose levels in pre-diabetes patients and type 2 diabetes patients; and IPOXYN, an injectable drug to prevent necrosis, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. It is also developing BTI-410, a peptide injectable compound, which is in Phase II clinical trial to stimulate beta cell maturation for development as a new insulin producing cell agent for the pancreas in type 2 diabetes patients and type 1 patients who are on immunosuppression therapy after having undergone kidney transplant surgery; SUGARDOWN, a non-systemic polysaccharide based dietary supplement to support healthy blood glucose levels; and OXYFEX, a veterinary medicine application used as an oxygen delivery agent similar to a RBC replacement for ischemia and trauma, as well as for blood loss during surgery. In addition, the company provides automatic retinal image analysis (ARIA), a diagnostic device for screening of cardiovascular risk, such as stroke. Boston Therapeutics, Inc. is headquartered in Lawrence, Massachusetts.
Visit WebsiteEarnings History & Surprises
NNMXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | Apr 5, 2024 | — | — | — | — |
Q1 2024 | Jan 15, 2024 | — | — | — | — |
Q4 2023 | Nov 27, 2023 | — | — | — | — |
Q3 2023 | Sep 28, 2023 | — | — | — | — |
Q2 2023 | Apr 7, 2023 | — | — | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.09 | — | — |
Q4 2022 | Nov 14, 2022 | — | $-0.10 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.08 | — | — |
Q2 2022 | May 17, 2022 | — | $-0.15 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.12 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.47 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-2.92 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.99 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-1.25 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-1.22 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-1.95 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.00 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-0.00 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.00 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.01 | — | — |
Latest News
Frequently Asked Questions about NNMX
What is NNMX's current stock price?
What is the analyst price target for NNMX?
What sector is Nanomix Corporation in?
What is NNMX's market cap?
Does NNMX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NNMX for comparison